MANAGEMENT OF MYELODYSPLASTIC SYNDROMES
1993; Wiley; Volume: 84; Issue: 2 Linguagem: Inglês
10.1111/j.1365-2141.1993.tb03051.x
ISSN1365-2141
Autores Tópico(s)Retinoids in leukemia and cellular processes
ResumoBritish Journal of HaematologyVolume 84, Issue 2 p. 191-196 MANAGEMENT OF MYELODYSPLASTIC SYNDROMES W. J. R. Hirst, W. J. R. Hirst Department of Haematological Medicine, King's College Hospital School of Medicine and Dentistry, LondonSearch for more papers by this authorG. J. Mufti, Corresponding Author G. J. Mufti Department of Haematological Medicine, King's College Hospital School of Medicine and Dentistry, LondonDr G. J. Mufti, Department of Haematological Medicine, King's College Hospital School of Medicine and Dentistry. London SE5 9RS.Search for more papers by this author W. J. R. Hirst, W. J. R. Hirst Department of Haematological Medicine, King's College Hospital School of Medicine and Dentistry, LondonSearch for more papers by this authorG. J. Mufti, Corresponding Author G. J. Mufti Department of Haematological Medicine, King's College Hospital School of Medicine and Dentistry, LondonDr G. J. Mufti, Department of Haematological Medicine, King's College Hospital School of Medicine and Dentistry. London SE5 9RS.Search for more papers by this author First published: June 1993 https://doi.org/10.1111/j.1365-2141.1993.tb03051.xCitations: 12AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES Appelbaum, F.R., Barall, J., Storb, R., Fischer, L., Schoch, G., Ramberg, R., Shulman, H., Anasetti, C., Bearman, S., Beatty, P., Bensinger, W., Buckner, D., Clift, R., Hansen, J., Martin, P., Petersen, F., Sanders, J., Singer, J., Stewart, P., Sullivan, K., Witherspoon, R. & Thomas, D. (1990) Bone marrow transplantation for patients with myelodysplasia. Annals of Internal Medicine, 112, 590– 597. Armitage, J.O., Dick, F.R., Needleman, S.W. & Burns, C.P. (1981) Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treatment Reports, 65, 601– 605. Aul, C. & Schneider, W. (1990) Treatment of advanced myelodys-plastic syndrome: trend towards more aggressive chemotherapy. Haematology and Blood Transfusion: Acute Leukaemia II, 33, 382– 388. Aul, C., Gatterman, N., Axel, H., Germing, U., Derigs, G. & Schneider, W. (1992a) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukaemia, 6, 52– 59. Aul, C., Gattermann, N. & Schneider, W. (1992b) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. British Journal of Haematology, 82, 358– 367. Bagby, G.C., Gobourel, J.D. & Linman, J.W. (1980) Glucocorticoid therapy in the preleukaemic syndrome (haemopoietic dysplasia): identification of responsive patients using in vitro techniques. Annals of Internal Medicine, 92, 55– 58. Bandini, G., Rosti, G., Calori, E., Albertazzi, L. & Tura, S.S. (1990) Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome. British Journal of Haematology, 75, 442– 444. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189– 199. Bowen, D., Culligan, D. & Jacobs, A. (1991) The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. British Journal of Haematology, 77, 419– 423. Cannistra, S.A. & Griffin, J.D. (1990) Granulocyte-macrophage colony stimulating factor enhances cytotoxic effect of cytosine arabinoside in acute myeloid leukaemia. Third Symposium on Minimal Residual Disease in Acute Leukaemia, Rotterdam , The Netherlands . Cheson, B.D., Jasperse, D.M., Simon, R. & Friedman, M.A. (1986) A critical appraisal of low dose cytosine arabinoside in patients with acute non-lymphocytic leukaemia and myelodysplastic syndromes. Journal of Clinical Oncology, 4, 1857– 1864. De Witte, T., Muus, P., De Pauw, B. & Haanen, C. (1990a) Intensive antileukemic treatment of patients with myelodysplastic syndromes and secondary acute myelogenous leukaemia. Cancer, 66, 831– 837. De Witte, T., Zwaan, F., Hermans, J., Vernant, J., Kolb, H., Vossen, J., Lonnqvist, B., Beclen, D., Ferrant, A., Gmur, J., Lin Yiu, J., Troussard, X., Cahn, J., Van Lint, M. & Gratwohl, A. (1990b) Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: A survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). British Journal of Haematology, 74, 151– 155. Elias, L., Hoffman, R., Boswell, S., Tensen, L. & Bonnem, E.M. (1987) A trial of recombinant alpha2-interferon in myelodysplastic syndromes. I. Clinical results. Leukaemia, 1, 105– 110. Estey, E., Kurzrock, R., Talpaz, M., McCreadie, K., O'Brien, S., Kantarjian, H.M., Keating, M.J., Deisseroth, A.B. & Gutterman, J. (1989) Therapy of myelodysplastic syndromes (MDS) with GM-CSF. Proceedings of the American Society of Clinical Oncology, 8, 200. Estey, E., Kurzrock, R., Talpaz, M., McCreadie, K., O'Brien, S., Kantarjian, H.M., Keating, M.J., Deisseroth, A.B. & Gutterman, J. (1992) Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. British Journal of Haematology, 77, 291– 295. Fenaux, P., Morel, P., Rose, C., Lai, J.L., Jouet, J.P. & Bauters, F. (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology, 77, 497– 501. Gajewski, J.L., Ho, W.G., Feig, S.A., Hunt, L., Kaufman, N. & Champlin, R.E. (1990) Bone marrow transplantation using unrelated donors for patients with advanced leukaemia or bone marrow failure. Transplantation, 50, 244– 249. Ganser, A. (1992) Treatment of myelodysplastic syndromes with hemopoietic growth factors. Hematology/Oncology Clinics of North America, 6, 633– 653. Ganser, A., Volkes, B., Greher, J., Ottman, O.G., Walther, F., Becher, R., Bergman, L., Schultz, G. & Hoelzer, D. (1989) Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes—a phase I/II trial. Blood, 73, 31– 37. Gerhartz, H., Marcus, R., Delmer, A., Zwierzina, H., de Witte, T., Jacobs, A., Visani, G., Fiere, D., Sonneveld, P., Labar, B., Hoffbrand, A.V., Fenaux, P., Hagat, M., Thyss, A., Debucher, L., Coiffier, B., Sizoo, W., Willemze, R., Ribeiro, M., Sucius, S., Solbu, G., Stern, A. & Zittoun, R. (1990) Randomised phase II trial with granulocyte-macrophage colony stimulating factor and low dose cytosine arabinoside in patients with ‘high risk’ myelodysplastic syndromes (MDS). (Abstract 1086). Blood, 76 (Suppl.), 274a. Greenburg, P.L. (1986) In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders. Clinics in Haematology, 15, 973– 993. Greenburg, P.L. (1992) In vitro marrow culture studies in the myelodysplastic syndromes. Seminars in Oncology, 19, 34– 46. Hellström-Linberg, E., Robert, K.H., Gahrton, G., Linberg, G., Forsblom, A.H., Kock, Y. & Ost, A. (1992) A predictive model for the clinical response to low dose cytosine arabinoside; a study of 102 patients with myelodysplastic syndromes or acute leukaemia. British Journal of Haematology, 81, 503– 511. Hoelzer, D., Ganser, A., Seipelt, G., Ottman, O., Hoffken, K., Boogaerts, M., Verhaef, G., Lutz, D., Krieger, O., de Witte, T., Diehl, V., Lathan, B., Ferrant, A., Martiat, P., Klausmann, M., Gangji, D., Frisch, J. & Schulz, G. (1989) Simultaneous treatment with recombinant human granulocyte-macrophage colony-stimulating factor and low dose cytosine arabinoside in patients with myelodysplastic syndromes. (Abstract 439). Blood, 74 (Suppl.), 118a. Huang, M., Ye, H.C., Chen, S.R., Chai, J.R., Lu, J.X., Zhoa, L., Gu, L.J. & Wang, Z.Y. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567– 572. Jensen, P.D., Jensen, I.M. & Ellegaard, J. (1992) Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. British Journal of Haematology, 80, 121– 124. Kaczmarski, R.S., Pozniak, A., Lakhai, A., Harvey, E. & Mufti, G.J. (1993) A pilot study of low dose recombinant human granulocyte-macrophage colony-stimulating factor in chronic neutropenia. British Journal of Haematology, 84, 338– 340. Kantarjian, H.M., Keating, M.J., Walters, R.S., Smith, T.L., Cork, A., McCredie, K.B. & Freireich, E.J. (1986) Therapy-related leukaemia and myelodysplastic syndromes: clinical, cytogenetic and prognostic factors. Journal of Clinical Oncology, 4, 1748– 1757. Koeffler, H.P., Heitjan, D., Mertelsmann, R., Kolitz, J.E., Schulman, P., Itri, L., Gunter, P. & Besa, E. (1988) Randomised study of 13-cis retinoic acid versus placebo in the myelodysplastic disorders. Blood, 71, 703– 708. Koeffler, H.P., Hirji, K. & Itri, L. (1985) 1, 25-dihydroxyvitamin D3: in vitro and in vivo effects on human preleukaemic and leukaemic cells. Cancer Treatment Research, 69, 1399– 1407. Layton, D.M. (1992) The molecular biology of myelodysplastic syndromes (preleukaemia). In: The Myelodysplastic Syndromes (Ed. by G. Mufti and D. Galton). Churchill Livingstone, Edinburgh . Longmore, G., Giunan, E.C., Weinstein, H.J., Gelber, R.D., Rappeport, J.M. & Antin, J.H. (1990) Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukaemia. Journal of Clinical Oncology, 8, 1707– 1714. Lotem, J. & Sachs, L. (1980) Potential pre-screening for therapeutic agents that induce differentiation in human myeloid leukaemia cells. International Journal of Cancer, 25, 561– 564. Maiolo, A.T., Cortelezzi, A., Calori, R. & Polli, E.E. (1990) Recombinant alpha-interferon as the first line therapy for high risk myelodysplastic syndromes. Italian MDS Study Group. Leukaemia, 4, 480– 485. Mertelsmann, R., Thaler, H.T., To, L., Gee, T.S., McKenzie, S., Schauer, P., Friedman, A., Arlin, Z., Cirrincione, C. & Clarkson, B. (1980) Morphological classification, response to therapy and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood, 56, 773– 781. Michels, S., Saumur, J., Arthur, D., Robinson, L. & Brunning, R. (1989) Refractory anaemia with excess of blasts in transformation; hematologic and clinical study of 52 patients. Cancer, 64, 2340– 2346. Miller, K.B., Kim, K., Morrison, F.S., Winter, J.N., Bennett, J.M., Cassileth, P.A., Grever, M., Oken, M. & Head, D. (1988) Evaluation of low dose ara-C versus supportive care in the treatment of myelodysplastic syndromes: An intergroup study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group. (Abstract 771). Blood, 72, (Suppl.), 215a. Mufti, G.J. (1992) A guide to risk assessment in primary myelodys-plastic syndromes. Hematology/Oncology Clinics of North America, 6, 587– 606. Mufti, G.J., Stevens, J.R., Oscier, D.G., Hamblin, T.J. & Machin, D. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. British Journal of Haematology, 65, 73– 81. Najean, Y. & Pecking, R. (1977) Refractory anaemia with excess myeloblasts in the bone marrow; a clinical trial of androgens in 90 patients. British Journal of Haematology, 37, 25– 33. Negrin, R.S., Nagler, A. & Kobayashi, Y. (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood, 78, 36– 43. Oscier, D.G., Worsley, A., Hamblin, T.J. & Mufti, G.J. (1989) Treatment of chronic myelomonocytic leukaemia with low dose etoposide. British Journal of Haematology, 72, 468– 471. Ossenkoppele, G.J., Wijermans, P.W., Nauta, J.J., Huijgens, P.C. & Langenhuijsen, M.M. (1991) Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: in vivo and in vitro cytotoxicity. European Journal of Cancer, 27, 842– 845. Owens, M.R. & Bennett, J.M. (1988) Effectiveness of attenuated chemotherapy in myelodysplastic syndromes: a preliminary report. Medical Pediatric Oncology, 16, 107– 110. Pedersen-Bjergaard, J., Philip, P., Larsen, S.O., Jensen, G. & Byrsting, K. (1990) Chromosomal aberrations and prognostic factors in therapy-related myelodysplasia and acute non-lymphocytic leukemia. Blood, 76, 1083– 1091. Razzano, M., Caslini, C., Cortelazzo, S., Battistel, V., Rambaldi, A. & Barbui, T. (1992) Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes. British Journal of Haematology, 81, 6628– 6630. Schouten, H.C., Vellenga, E., van Rhenen, D.J., de Wolf, J.T.M., Coppens, P.J.W. & Blijham, G.H. (1991) Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukaemia, 5, 432– 436. Schuster, M.W., Larson, R., Thompson, J.A., Coiffier, B., Bennett, J.M. & Israel, R.J. (1990) Granulocyte-macrophage colony-stimulating factor for myelodysplastic syndromes (MDS): results of a multicentre randomized controlled trial. (Abstract 1263). Blood, 76 (Suppl.), 318a. Solal-Celigny, P., Desaint, B., Hewara, A., Chastanga, L., Amar, M., Vrodans, M., Brousse, N., Mancilla, F., Renoux, M., Bernard, J.F. & Bolrin, P. (1984) Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Blood, 63, 634– 638. Stein, R.S., Abels, R.I. & Krantz, S.B. (1991) Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood, 78, 1658– 1663. Tefferi, A., Hoagland, H., Therneau, T. & Pierre, R. (1989) Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clinic Proceedings, 64, 1246– 1254. Tricot, G. & Boogaerts, M.A. (1986) The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. British Journal of Haematology, 63, 477– 483. Willemze, R., Visani, G., de Witte, T., Zwierzina, H., Labar, B., Jacobs, A., Gerhartz, H., Haak, H.L., Stern, A.C., Suciu, S., Solbu, G. & Zittoun, R. (1990) A randomized phase I/II study with recombinant human GM-CSF in patients (pts) with myelodysplastic syndromes at a relatively low risk of developing acute leukemia. (Abstract 1337). Blood, 76, (Suppl.), 337a. Yoshida, Y., Hirashima, K., Asano, S. & Takaku, F. (1991) A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. British Journal of Haematology, 78, 378– 384. Yoshida, Y., Yamagishi, M., Oguma, S.S., Oguma, S., Uchino, H. & Maekawa, T. (1988) Conservative treatment for refractory myelodysplastic anaemias. A Japanese Cooperative Study. Acta Haematologica Japanica, 51, 1448– 1454. Zittoun, R. (1992) Chronic myelomonocytic leukaemia. In: The Myelodysplastic Syndromes (Ed. by G. Mufti and D. Galton). Churchill Livingstone, Edinburgh . Citing Literature Volume84, Issue2June 1993Pages 191-196 ReferencesRelatedInformation
Referência(s)